Condition
Digital Ulcers
Total Trials
7
Recruiting
0
Active
0
Completed
6
Success Rate
85.7%-1% vs avg
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
85.7%
-0.8% vs benchmark
Late-Stage Pipeline
71%
5 trials in Phase 3/4
Results Transparency
50%
3 of 6 completed with results
Key Signals
3 with results86% success
Data Visualizations
Phase Distribution
6Total
P 2 (1)
P 3 (4)
P 4 (1)
Trial Status
Completed6
Terminated1
Trial Success Rate
85.7%
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT01474122Phase 3TerminatedPrimary
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
NCT00319696Phase 3CompletedPrimary
Bosentan in Digital Ulcers
NCT00077584Phase 3CompletedPrimary
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
NCT01395732Phase 4Completed
Bosentan in Systemic Sclerosis
NCT02915835Phase 2Completed
Riociguat in Scleroderma Associated Digital Ulcers
NCT01377090Completed
Digital Ulceration
NCT01117298Phase 3Completed
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Showing all 7 trials